



## The Drug Utilization Review Board Reviewed the Following New Drugs and Classes on December 11, 2012

The Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health's (DCH) final decisions on the following new drugs and classes for the Georgia Medicaid FFS Preferred Drug List (PDL). The current PDL is located at <http://dch.georgia.gov/pharmacy> under the Preferred Drug Lists link or directly at [http://dch.georgia.gov/00/channel\\_title/0,2094,31446711\\_32050640,00.html](http://dch.georgia.gov/00/channel_title/0,2094,31446711_32050640,00.html).

### New Drug Reviews

#### Enzyme Replacement

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Elelyso*<sup>™</sup>.

#### Hormone Modifier

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Korlym*<sup>™</sup>.

#### Anticonvulsant

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Potiga*<sup>™</sup>.

### Class Reviews

#### Antiretrovirals for Human Immunodeficiency Virus (HIV)

The DUR Board recommended *No Changes* from the current PDL status. The DUR Board also recommended the Department report on prior authorization and utilization data at the June 6, 2012 meeting.